Please use this identifier to cite or link to this item: http://arl.liuc.it/dspace/handle/2468/6194
Title: Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: Efficacy and cost of the prophylaxis in a retrospective survey
Authors: Innocenti, Rolando
Rigacci, Luigi
Restelli, Umberto
Scappini, Barbara
Gianfaldoni, Giacomo
Fanci, Rosa
Mannelli, Francesco
Scolari, Francesca
Croce, Davide
Bonizzoni, Erminio
Perrone, Tania
Bosi, Alberto
Issue Date: 2019
Publisher: Dove press
Bibliographic citation: Innocenti Rolando, et al. (2019), Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey. In: Journal of blood medicine, vol. 10, 2019, p. 21-27. ISSN 1179-2736. DOI 10.2147/JBM.S186786.
Abstract: Purpose: We conducted a retrospective study to evaluate the efficacy and related costs of using two different molecules of granulocyte-colony stimulating factor (G-CSF) (lenograstim – LENO or filgrastim – FIL) as primary prophylaxis of chemotherapy-induced neutropenia in a hematological inpatient setting. Methods: The primary endpoints of the analysis were the efficacy of the two G-CSFs in terms of the level of white blood cells, hemoglobin and platelets at the end of the treatment and the per capita direct medical costs related to G-CSF prophylaxis. Results: Two hundred twelve patients (96 LENO, 116 FIL) have been evaluated. The following statistically significant differences have been observed between FIL and LENO: the use of a higher number of vials (11 vs 7; P<0.03) to fully recover bone marrow, a higher grade 3–4 neutropenia at the time of G-CSF discontinuation (29.3% vs 16.7%; P=0.031) and an increased number of days of hospitalization (8 vs 5; P<0.005). A longer hospital stay before discharge was necessary (12 vs 10), which reflects the higher final costs per patient (median treatment cost per cycle 10.706 € for LENO, compared to 12.623 € for FIL). Conclusion: The use of LENO has been associated with a lower number of days of hospitalization, number of vials and less incidence of grade 3–4 neutropenia at the time of G-CSF discontinuation. LENO seems to be cost-saving when compared with FIL (–15.2%).
URI: http://arl.liuc.it/dspace/handle/2468/6194
Journal/Book: Journal of blood medicine
ISSN: 1179-2736
Appears in Collections:Contributo in rivista

Files in This Item:
File Description SizeFormat 
6194.pdf
  Restricted Access
470,75 kBAdobe PDFView/Open Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.